Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Dulaglutide (Trulicity) vs Lixisenatide (Adlyxin)
An educational, source-based comparison of Dulaglutide (Trulicity) and Lixisenatide (Adlyxin) — how each peptide works, what it's researched for, and what to know before going deeper.
Once-weekly GLP-1 agonist with cardiovascular benefit.
GLP-1 analog fused to a modified human IgG4 Fc fragment, giving a half-life that supports weekly dosing. Improves glycemia and reduces MACE in T2D.
- Type 2 diabetes
- Cardiovascular risk reduction in T2D
- • FDA-approved.
- • Boxed warning: thyroid C-cell tumors in rodents.
Short-acting GLP-1 agonist focused on postprandial glucose.
Exendin-4 derivative with potent postprandial glucose-lowering effect via delayed gastric emptying and enhanced insulin response.
- Type 2 diabetes
- Postprandial hyperglycemia
- • FDA-approved.
- • GI side effects common.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
FDA-approved with published clinical trial data.
FDA-approved with published clinical trial data.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| Dulaglutide (Trulicity) | REWIND trial | Lancet | 2019 | Reduced major adverse cardiovascular events in T2D patients with or without prior CV disease. |
| Lixisenatide (Adlyxin) | ELIXA trial | NEJM | 2015 | Cardiovascular safety in T2D patients post-ACS. |
Side-effect & safety grid
- FDA-approved.
- Boxed warning: thyroid C-cell tumors in rodents.
- FDA-approved.
- GI side effects common.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
Dulaglutide (Trulicity) vs Lixisenatide (Adlyxin) — Key differences
- Class: Dulaglutide (Trulicity) is classified as GLP-1 Agonist · Metabolic, while Lixisenatide (Adlyxin) is GLP-1 Agonist · Metabolic.
- Primary research focus: Dulaglutide (Trulicity) — type 2 diabetes; Lixisenatide (Adlyxin) — type 2 diabetes.
- Tag: FDA-Approved · Metabolic vs FDA-Approved · Metabolic.